Do analysts rate CURX or ATNM?

Actinium Pharmaceuticals has a consensus price target of $4.50, suggesting a potential upside of 303.59%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is CURX or ATNM more profitable?

Curanex Pharmaceuticals' return on equity of -85.41% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -85.41% -82.11% Actinium Pharmaceuticals N/A -100.85% -47.89%

Do analysts prefer GRCE or CURX?

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 149.48%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Grace Therapeutics is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, GRCE or CURX?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$9.57M -$0.40 N/A Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A

Is GRCE or CURX more profitable?

Grace Therapeutics' return on equity of -15.58% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -15.58% -14.51% Curanex Pharmaceuticals N/A -85.41% -82.11%

Do analysts rate CURX or ATHE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, CURX or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is CURX or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -85.41% -82.11% Alterity Therapeutics N/A N/A N/A

Do analysts prefer TVGN or CURX?

Tevogen Bio currently has a consensus target price of $100.00, indicating a potential upside of 955.97%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Tevogen Bio is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, TVGN or CURX?

Tevogen Bio is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A

Is TVGN or CURX more profitable?

Tevogen Bio's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% Curanex Pharmaceuticals N/A -85.41% -82.11%

Do analysts prefer CURX or ADXS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CURX or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -85.41% -82.11% Ayala Pharmaceuticals N/A N/A N/A

Curanex Pharmaceuticals (CURX) Competitors

$0.34 +0.01 (+4.15%)

As of 04:00 PM Eastern

Compare

CURX vs. ATNM, GRCE, ATHE, TVGN, and ADXS

Should you buy Curanex Pharmaceuticals stock or one of its competitors? MarketBeat compares Curanex Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Curanex Pharmaceuticals include Actinium Pharmaceuticals (ATNM), Grace Therapeutics (GRCE), Alterity Therapeutics (ATHE), Tevogen Bio (TVGN), and Ayala Pharmaceuticals (ADXS). These companies are all part of the "pharmaceutical products" industry.

How does Curanex Pharmaceuticals compare to Actinium Pharmaceuticals?

Curanex Pharmaceuticals (NASDAQ:CURX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, Actinium Pharmaceuticals had 7 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 7 mentions for Actinium Pharmaceuticals and 0 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.89 beat Actinium Pharmaceuticals' score of 0.00 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Very Positive
Actinium Pharmaceuticals	Neutral

Actinium Pharmaceuticals has a consensus price target of $4.50, suggesting a potential upside of 303.59%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Curanex Pharmaceuticals' return on equity of -85.41% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Curanex Pharmaceuticals has higher earnings, but lower revenue than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
Actinium Pharmaceuticals	$90K	388.70	-$48.82M	-$0.75	N/A

Summary

Actinium Pharmaceuticals beats Curanex Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

6.1% of Grace Therapeutics shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

Grace Therapeutics' return on equity of -15.58% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-15.58%	-14.51%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 149.48%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Grace Therapeutics is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Grace Therapeutics had 2 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 2 mentions for Grace Therapeutics and 0 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.89 beat Grace Therapeutics' score of 0.87 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Grace Therapeutics	Positive
Curanex Pharmaceuticals	Very Positive

Summary

Grace Therapeutics beats Curanex Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Alterity Therapeutics?

Curanex Pharmaceuticals (NASDAQ:CURX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Alterity Therapeutics' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
Alterity Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

2.1% of Alterity Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Curanex Pharmaceuticals' average media sentiment score of 1.89 beat Alterity Therapeutics' score of 1.43 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Very Positive
Alterity Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Alterity Therapeutics beats Curanex Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Tevogen Bio is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

Tevogen Bio's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

In the previous week, Tevogen Bio had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.89 beat Tevogen Bio's score of 0.87 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Tevogen Bio	Positive
Curanex Pharmaceuticals	Very Positive

Tevogen Bio currently has a consensus target price of $100.00, indicating a potential upside of 955.97%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Tevogen Bio is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Curanex Pharmaceuticals beats Tevogen Bio on 5 of the 9 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Ayala Pharmaceuticals?

Curanex Pharmaceuticals (NASDAQ:CURX) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.89 beat Ayala Pharmaceuticals' score of 0.00 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Very Positive
Ayala Pharmaceuticals	Neutral

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ayala Pharmaceuticals' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
Ayala Pharmaceuticals	N/A	N/A	N/A

Curanex Pharmaceuticals has higher earnings, but lower revenue than Ayala Pharmaceuticals. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Summary

Ayala Pharmaceuticals beats Curanex Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Get Curanex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CURX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CURX vs. The Competition

Export

Metric	Curanex Pharmaceuticals	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$9.73M	$984.12M	$4.36B	$12.47B
Dividend Yield	N/A	4.84%	7.42%	5.22%
P/E Ratio	-1.27	1.46	21.82	24.40
Price / Sales	N/A	125.15	175.40	117.01
Price / Cash	N/A	20.06	58.60	57.13
Price / Book	0.86	8.11	30.96	6.73
Net Income	-$4.22M	-$3.91M	$109.80M	$337.03M
7 Day Performance	0.03%	-1.73%	-0.33%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	N/A	111.98%	15.69%	34.24%

Curanex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CURX Curanex Pharmaceuticals	1.4884 of 5 stars	$0.34 +5.4%	N/A	N/A	$9.73M	N/A	N/A	N/A	Positive News
ATNM Actinium Pharmaceuticals	2.2825 of 5 stars	$1.18 +1.7%	$4.50 +281.4%	-31.0%	$37.02M	$90K	N/A	30	News Coverage Gap Up
GRCE Grace Therapeutics	2.6709 of 5 stars	$2.33 -1.3%	$6.00 +157.5%	-13.1%	$36.52M	N/A	N/A	N/A	News Coverage
ATHE Alterity Therapeutics	1.3599 of 5 stars	$4.05 -0.7%	N/A	-13.5%	$36.18M	N/A	N/A	10	Positive News Short Interest Decrease
TVGN Tevogen Bio	1.9069 of 5 stars	$7.19 -16.4%	$100.00 +1,290.8%	-85.8%	$35.81M	N/A	N/A	3	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CURX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. ATNM, GRCE, ATHE, TVGN, and ADXS

How does Curanex Pharmaceuticals compare to Actinium Pharmaceuticals?

Summary

How does Curanex Pharmaceuticals compare to Grace Therapeutics?

Summary

How does Curanex Pharmaceuticals compare to Alterity Therapeutics?

Summary

How does Curanex Pharmaceuticals compare to Tevogen Bio?

Summary

How does Curanex Pharmaceuticals compare to Ayala Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. ATNM, GRCE, ATHE, TVGN, and ADXS

How does Curanex Pharmaceuticals compare to Actinium Pharmaceuticals?

Does the media refer more to CURX or ATNM?

Do analysts rate CURX or ATNM?

Is CURX or ATNM more profitable?

Do insiders & institutionals hold more shares of CURX or ATNM?

Which has preferable earnings & valuation, CURX or ATNM?

Summary

How does Curanex Pharmaceuticals compare to Grace Therapeutics?

Do institutionals and insiders believe in GRCE or CURX?

Which has higher earnings & valuation, GRCE or CURX?

Is GRCE or CURX more profitable?

Do analysts prefer GRCE or CURX?

Does the media prefer GRCE or CURX?

Summary

How does Curanex Pharmaceuticals compare to Alterity Therapeutics?

Is CURX or ATHE more profitable?

Which has better earnings and valuation, CURX or ATHE?

Do insiders & institutionals hold more shares of CURX or ATHE?

Does the media favor CURX or ATHE?

Do analysts rate CURX or ATHE?

Summary

How does Curanex Pharmaceuticals compare to Tevogen Bio?

Which has preferable valuation & earnings, TVGN or CURX?

Is TVGN or CURX more profitable?

Does the media refer more to TVGN or CURX?

Do analysts prefer TVGN or CURX?

Summary

How does Curanex Pharmaceuticals compare to Ayala Pharmaceuticals?

Does the media prefer CURX or ADXS?

Do insiders & institutionals hold more shares of CURX or ADXS?

Do analysts prefer CURX or ADXS?

Is CURX or ADXS more profitable?

Which has preferable valuation & earnings, CURX or ADXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools